Exelixis (EXEL) Gets Longer FDA Review As Cancer Pipeline Milestone Advances

• Exelixis (NasdaqGS:EXEL) reported that the FDA extended its review of the zanzalintinib NDA in metastatic colorectal cancer after new safety and efficacy data submissions.
• The regulator added time to the review clock following Exelixis' update to the application, which included additional clinical information.
• Exelixis reached a collaboration milestone with Adagene in their antibody drug conjugate program, triggering a contractual milestone payment.
• The FDA's extended zanzalintinib review and Adagene milestone only capture one slice of Exelixis' broader pipeline story. Take a look at 4 other big wins we have identified for Exelixis.

For a wider view on how drug development and data driven research are intersecting across healthcare, expand your search with 39 healthcare AI stocks.

Exelixis focuses on developing cancer treatments, so the zanzalintinib filing and the antibody drug conjugate work with Adagene both sit squarely within its push to bring new options to patients with difficult-to-treat tumors in the US.

Does the team leading Exelixis have what it takes? See our full breakdown of the management team's track record and compensation.

Exelixis news that tests the colorectal cancer bet

The Narrative around Exelixis is that CABOMETYX funds a second oncology franchise, with colorectal and neuroendocrine tumors gradually reshaping a one drug story into a broader portfolio. This FDA delay and the Adagene milestone both speak directly to whether that diversification effort has real depth.

"Positive top-line results from pivotal trials (e.g., STELLAR-303 for zanzalintinib in colorectal cancer) and an advancing late-stage pipeline provide significant potential for new product approvals and label expansions..."

See how the full story points towards a $53.00 fair value for Exelixis.

The market reaction to the extended zanzalintinib review focuses on timing, not what it signals about Exelixis trying to build a second pillar beyond cabozantinib. Fresh safety and efficacy data strong enough to count as a major amendment suggest the colorectal opportunity is being refined, not parked, even if the March 2027 action date pushes the decision out.

In contrast, the Adagene milestone reminds you that management is funding multiple biologics programs while CABOMETYX still dominates the income statement. That steady spend on antibody drug conjugates puts Exelixis up against players like Seagen and Daiichi Sankyo in a crowded modality, and it cuts both ways for the thesis that disciplined capital allocation can offset patent and pricing risks.

For investors, this update only really matters in the context of which story you buy into for Exelixis, a single drug cash engine slowly broadening out or a pipeline that never quite catches up.

The Exelixis forecast curve most holders never pull up

One quiet set of numbers sketches where analysts think Exelixis could be a few years from now, and that projected destination looks very different to what today’s headlines suggest. See where analysts expect Exelixis to be in a few years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com